Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Toviaz
TOVIAZ 4 mg prolonged-release tablets TOVIAZ 8 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-117260 · Präparat HOS-094561
Potent CYP3A4 inhibitors
Following inhibition of CYP3A4 by co-administration of ketoconazole 200 mg twice daily, Cmax and
AUC of the active metabolite of fesoterodine increased 2.0 and 2.3-fold in CYP2D6 extensive
metabolisers and 2.1 and 2.5-fold in CYP2D6 poor metabolisers, respectively. Therefore, the
maximum dose of fesoterodine should be restricted to 4 mg when used concomitantly with potent
CYP3A4 inhibitors (e.g. atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone,
nelfinavir, ritonavir (and all ritonavir boosted PI-regimens), saquinavir and telithromycin (see
sections 4.2 and 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) nefazodone (HOS-084519) atazanavir (HOS-086180) nelfinavir (HOS-084520) ketoconazole (HOS-084513) telithromycin (HOS-084523) itraconazole (HOS-084516) saquinavir (HOS-084522) clarithromycin (HOS-084517) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-04T15:52:00Z · SHA-256 c9fd9fb2f6c8ee3d5e56c913ba09d40147211dee6df16329539fa6b5e813accb · Passage 679ac7be8f845fe7a62693f49c65460a286580b97dd43cc2c87699cd8e06bb99 · Zeichen 898–1520 im Abschnitt
Wechselwirkungen · Abraxane
Abraxane 5 mg/ml powder for dispersion for infusion. · Abschnitt 4.5 · PDF-Seite 9
HOS-117861 · Präparat HOS-094711
The metabolism of paclitaxel is catalysed, in part, by cytochrome P450 isoenzymes CYP2C8 and
CYP3A4 (see section 5.2). Therefore, in the absence of a PK drug-drug interaction study, caution
should be exercised when administering paclitaxel concomitantly with medicines known to inhibit
either CYP2C8 or CYP3A4 (e.g. ketoconazole and other imidazole antifungals, erythromycin,
fluoxetine, gemfibrozil, clopidogrel, cimetidine, ritonavir, saquinavir, indinavir, and nelfinavir)
because toxicity of paclitaxel may be increased due to higher paclitaxel exposure. Administering
paclitaxel concomitantly with medicines known to induce either CYP2C8 or CYP3A4 (e.g. rifampicin,
carbamazepine, phenytoin, efavirenz, nevirapine) is not recommended because efficacy may be
compromised because of lower paclitaxel exposures.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) nelfinavir (HOS-084520) cimetidine (HOS-085835) ketoconazole (HOS-084513) carbamazepine (HOS-085618) gemfibrozil (HOS-088403) imidazole (HOS-117862) saquinavir (HOS-084522) clopidogrel (HOS-087927) erythromycin (HOS-084514) fluoxetine (HOS-085946) efavirenz (HOS-087947) nevirapine (HOS-088064) ritonavir (HOS-084521) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-21T09:38:00Z · SHA-256 38c462aa5de60951dcb4be6132b86a26b536e6a1309509e0d2888dd17f8022aa · Passage f250f391b1f7f31d44e77cb1f0e86c8273e473bb0bc0fc63253f2b40dbd561f3 · Zeichen 0–813 im Abschnitt
Wechselwirkungen · Celsentri
CELSENTRI 150 mg film-coated tablets CELSENTRI 300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9–10
HOS-118461 · Präparat HOS-094825
9
Indinavir Limited data are available for co-
administration with indinavir.
Indinavir is a potent CYP3A4
inhibitor. Population PK analysis in
phase 3 studies suggests dose
reduction of maraviroc when
co-administered with indinavir gives
appropriate maraviroc exposure.
Tipranavir/ritonavir Maraviroc AUC12 ↔ 1.02
500 mg/200 mg BID Maraviroc Cmax: ↔ 0.86
(maraviroc 150 mg BID) Tipranavir/ritonavir concentrations
were consistent with historical data.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) ritonavir (HOS-084521) tipranavir (HOS-086184)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-12T15:51:00Z · SHA-256 af7f0c7bbfd6e612d5a885c59ba9795f11ee85b00c3e0504de2a206af5fbec72 · Passage bd991c3179abdf1268b460ad7693cbf501ae394091a71c4ffff9eb91e9cf3ba2 · Zeichen 10535–11228 im Abschnitt
Wechselwirkungen · Celsentri
CELSENTRI 20 mg/mL oral solution · Abschnitt 4.5 · PDF-Seite 35–36
HOS-118504 · Präparat HOS-094825
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
35
Efavirenz 600 mg QD Maraviroc AUC12: ↓ 0.55 CELSENTRI dose should be
(maraviroc 100 mg BID) Maraviroc Cmax: ↓ 0.49 increased to 600 mg twice
Efavirenz concentrations not daily when co-administered
measured, no effect is expected. with efavirenz in the absence
of a potent CYP3A4 inhibitor.
For combination with
efavirenz + PI, see separate
recommendations below.
Etravirine 200 mg BID Maraviroc AUC12: ↓ 0.47 Etravirine is only approved
(maraviroc 300 mg BID) Maraviroc Cmax: ↓ 0.40 for use with boosted protease
inhibitors. For combination
Etravirine AUC12: ↔ 1.06 with etravirine + PI, see
Etravirine Cmax: ↔ 1.05 below.
Etravirine C12: ↔ 1.08
Nevirapine 200 mg BID Maraviroc AUC12: ↔ compared to Comparison to exposure in
(maraviroc 300 mg Single historical controls historical controls suggests
Dose) Maraviroc Cmax: ↑ compared to that CELSENTRI 300 mg
historical controls twice daily and nevirapine
Nevirapine concentrations not can be co-administered
measured, no effect is expected. without dose adjustment.
Protease Inhibitors (PIs)
Atazanavir 400 mg QD Maraviroc AUC12 ↑ 3.57 CELSENTRI dose should be
(maraviroc 300 mg BID) Maraviroc Cmax: ↑ 2.09 decreased to 150 mg twice
Atazanavir concentrations not daily when co-administered
measured, no effect is expected. with a PI; except in
Atazanavir/ritonavir Maraviroc AUC12 ↑ 4.88 combination with
300 mg/100 mg QD Maraviroc Cmax: ↑ 2.67 tipranavir/ritonavir where the
(maraviroc 300 mg BID) Atazanavir/ritonavir concentrations CELSENTRI dose should be
not measured, no effect is expected. 300 mg BID.
Lopinavir/ritonavir Maraviroc AUC12 ↑ 3.95
400 mg/100 mg BID Maraviroc Cmax: ↑ 1.97
(maraviroc 300 mg BID) Lopinavir/ritonavir concentrations not
measured, no effect is expected.
Saquinavir/ritonavir Maraviroc AUC12 ↑ 9.77
1000 mg/100 mg BID Maraviroc Cmax: ↑ 4.78
(maraviroc 100 mg BID) Saquinavir/ritonavir concentrations
not measured, no effect is expected.
Darunavir/ritonavir Maraviroc AUC12 ↑ 4.05
600 mg/100 mg BID Maraviroc Cmax: ↑ 2.29
(maraviroc 150 mg BID) Darunavir/ritonavir concentrations
were consistent with historical data.
Nelfinavir Limited data are available for co-
administration with nelfinavir.
Nelfinavir is a potent CYP3A4
inhibitor and would be expected to
increase maraviroc concentrations.
Indinavir Limited data are available for co-
administration with indinavir.
Indinavir is a potent CYP3A4
inhibitor. Population PK analysis in
phase 3 studies suggests dose
reduction of maraviroc when
co-administered with indinavir gives
appropriate maraviroc exposure.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) lopinavir (HOS-086269) atazanavir (HOS-086180) nelfinavir (HOS-084520) protease (HOS-085623) etravirine (HOS-088088) saquinavir (HOS-084522) darunavir (HOS-086181) efavirenz (HOS-087947) nevirapine (HOS-088064) ritonavir (HOS-084521) tipranavir (HOS-086184)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-12T15:51:00Z · SHA-256 af7f0c7bbfd6e612d5a885c59ba9795f11ee85b00c3e0504de2a206af5fbec72 · Passage 7650f006f70b016bab6056d849002bce692250e81f8df584dba8f3d456e3ce88 · Zeichen 6597–10790 im Abschnitt
Wechselwirkungen · Isentress
ISENTRESS 400 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-119062 · Präparat HOS-094905
Co-administration of raltegravir with medicinal products that are known to be potent UGT1A1
inhibitors (e.g., atazanavir) may increase plasma levels of raltegravir. Less potent UGT1A1 inhibitors
(e.g., indinavir, saquinavir) may also increase plasma levels of raltegravir, but to a lesser extent
compared with atazanavir. In addition, tenofovir disoproxil fumarate may increase plasma levels of
raltegravir, however, the mechanism for this effect is unknown (see Table 1). From the clinical trials, a
large proportion of patients used atazanavir and / or tenofovir disoproxil fumarate, both agents that
result in increases in raltegravir plasma levels, in the optimised background regimens. The safety
profile observed in patients who used atazanavir and / or tenofovir disoproxil fumarate was generally
similar to the safety profile of patients who did not use these agents. Therefore, no dose adjustment is
required.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) atazanavir (HOS-086180) saquinavir (HOS-084522) tenofovir disoproxil fumarate (HOS-110471)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-17T13:16:00Z · SHA-256 6b95e5ffe7a0fcf11532bc18fa0933606a4dfe39d9d876e4b916acb6d89e55cc · Passage 3a839151518fc386a23093bcb38a72d4923050db43352ef7ea31ce83433817cb · Zeichen 2267–3185 im Abschnitt
Wechselwirkungen · Isentress
ISENTRESS 25 mg chewable tablets ISENTRESS 100 mg chewable tablets · Abschnitt 4.5 · PDF-Seite 55
HOS-119220 · Präparat HOS-094905
Co-administration of raltegravir with medicinal products that are known to be potent UGT1A1
inhibitors (e.g., atazanavir) may increase plasma levels of raltegravir. Less potent UGT1A1 inhibitors
(e.g., indinavir, saquinavir) may also increase plasma levels of raltegravir, but to a lesser extent
compared with atazanavir. In addition, tenofovir disoproxil fumarate may increase plasma levels of
raltegravir, however, the mechanism for this effect is unknown (see Table 3). From the clinical trials, a
large proportion of patients used atazanavir and / or tenofovir disoproxil fumarate, both agents that
result in increases in raltegravir plasma levels, in the optimised background regimens. The safety
profile observed in patients who used atazanavir and / or tenofovir disoproxil fumarate was generally
similar to the safety profile of patients who did not use these agents. Therefore, no dose adjustment is
required.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) atazanavir (HOS-086180) saquinavir (HOS-084522) tenofovir disoproxil fumarate (HOS-110471)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-17T13:16:00Z · SHA-256 6b95e5ffe7a0fcf11532bc18fa0933606a4dfe39d9d876e4b916acb6d89e55cc · Passage 6e6c8a153ecbc37f9c77a6f51a3d423ec07dd1532fcd8f069a92f66e1b2693f4 · Zeichen 2267–3185 im Abschnitt
Wechselwirkungen · Isentress
ISENTRESS 100 mg granules for oral suspension · Abschnitt 4.5 · PDF-Seite 79
HOS-119292 · Präparat HOS-094905
Co-administration of raltegravir with medicinal products that are known to be potent UGT1A1
inhibitors (e.g., atazanavir) may increase plasma levels of raltegravir. Less potent UGT1A1 inhibitors
(e.g., indinavir, saquinavir) may also increase plasma levels of raltegravir, but to a lesser extent
compared with atazanavir. In addition, tenofovir disoproxil fumarate may increase plasma levels of
raltegravir, however, the mechanism for this effect is unknown (see Table 3). From the clinical trials, a
large proportion of patients used atazanavir and / or tenofovir disoproxil fumarate, both agents that
result in increases in raltegravir plasma levels, in the optimised background regimens. The safety
profile observed in patients who used atazanavir and / or tenofovir disoproxil fumarate was generally
similar to the safety profile of patients who did not use these agents. Therefore, no dose adjustment is
required.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) atazanavir (HOS-086180) saquinavir (HOS-084522) tenofovir disoproxil fumarate (HOS-110471)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-17T13:16:00Z · SHA-256 6b95e5ffe7a0fcf11532bc18fa0933606a4dfe39d9d876e4b916acb6d89e55cc · Passage 6e6c8a153ecbc37f9c77a6f51a3d423ec07dd1532fcd8f069a92f66e1b2693f4 · Zeichen 2266–3184 im Abschnitt
Wechselwirkungen · Intelence
INTELENCE 25 mg tablets INTELENCE 100 mg tablets INTELENCE 200 mg tablets · Abschnitt 4.5 · PDF-Seite 7–8
HOS-119734 · Präparat HOS-095005
7
NNRTIs
Efavirenz Combining two NNRTIs has not been shown to It is not recommended to
Nevirapine be beneficial. Concomitant use of etravirine co-administer INTELENCE
Rilpivirine with efavirenz or nevirapine may cause a with other NNRTIs.
significant decrease in the plasma concentration
of etravirine and loss of therapeutic effect of
etravirine.
Concomitant use of etravirine with rilpivirine
may cause a decrease in the plasma
concentration of rilpivirine and loss of
therapeutic effect of rilpivirine.
HIV Protease Inhibitors (PIs) – Unboosted (i.e. without co-administration of low-dose ritonavir)
Indinavir Concomitant use of etravirine with indinavir It is not recommended to
may cause a significant decrease in the plasma co-administer INTELENCE
concentration of indinavir and loss of with indinavir.
therapeutic effect of indinavir.
HIV PIs – Boosted with low-dose ritonavir
Atazanavir/ritonavir atazanavir INTELENCE and
300/100 mg once daily AUC ↓ 0.86 (0.79-0.93) atazanavir/ritonavir can be
Cmin ↓ 0.62 (0.55-0.71) used without dose
Cmax ↔ 0.97 (0.89-1.05) adjustment.
etravirine
AUC ↑ 1.30 (1.18-1.44)
Cmin ↑ 1.26 (1.12-1.42)
Cmax ↑ 1.30 (1.17-1.44)
Darunavir/ritonavir darunavir INTELENCE and
600/100 mg twice daily AUC ↔ 1.15 (1.05-1.26) darunavir/ritonavir can be
Cmin ↔ 1.02 (0.90-1.17) used without dose
Cmax ↔ 1.11 (1.01-1.22) adjustments (see also
etravirine section 5.1).
AUC ↓ 0.63 (0.54-0.73)
Cmin ↓ 0.51 (0.44-0.61)
Cmax ↓ 0.68 (0.57-0.82)
Fosamprenavir/ritonavir amprenavir Amprenavir/ritonavir and
700/100 mg twice daily AUC ↑ 1.69 (1.53-1.86) fosamprenavir/ritonavir may
Cmin ↑ 1.77 (1.39-2.25) require dose reduction when
Cmax ↑ 1.62 (1.47-1.79) co-administered with
etravirine INTELENCE. Using the oral
AUC ↔a solution may be considered
Cmin ↔a for dose reduction.
Cmax ↔a
Lopinavir/ritonavir lopinavir INTELENCE and
(tablet) AUC ↔ 0.87 (0.83-0.92) lopinavir/ritonavir can be
400/100 mg twice daily Cmin ↓ 0.80 (0.73-0.88) used without dose
Cmax ↔ 0.89 (0.82-0.96) adjustments.
etravirine
AUC ↓ 0.65 (0.59-0.71)
Cmin ↓ 0.55 (0.49-0.62)
Cmax ↓ 0.70 (0.64-0.78)
Saquinavir/ritonavir saquinavir INTELENCE and
1,000/100 mg twice daily AUC ↔ 0.95 (0.64-1.42) saquinavir/ritonavir can be
Cmin ↓ 0.80 (0.46-1.38) used without dose
Cmax ↔ 1.00 (0.70-1.42) adjustments.
etravirine
AUC ↓ 0.67 (0.56-0.80)
Cmin ↓ 0.71 (0.58-0.87)
Cmax ↓ 0.63 (0.53-0.75)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) lopinavir (HOS-086269) atazanavir (HOS-086180) protease (HOS-085623) saquinavir (HOS-084522) amprenavir (HOS-086183) rilpivirine (HOS-088090) darunavir (HOS-086181) efavirenz (HOS-087947) nevirapine (HOS-088064) fosamprenavir (HOS-086182) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-08-13T16:37:00Z · SHA-256 b6b2c3fd3d600c0f1fd17ddc8f6c1da50bcb8b2181089113d0397c5ec46864c4 · Passage 23dfafcde24735cb3cd88681ce12df0c18f7626edad5dad7f7170a308b3611a1 · Zeichen 3986–8467 im Abschnitt
Wechselwirkungen · Efient
Efient 10 mg film-coated tablets. Efient 5 mg film-coated tablets. · Abschnitt 4.5 · PDF-Seite 6
HOS-120775 · Präparat HOS-095209
Inhibitors of CYP3A:
Ketoconazole (400 mg daily), a selective and potent inhibitor of CYP3A4 and CYP3A5, did not affect
prasugrel-mediated inhibition of platelet aggregation or the prasugrel active metabolite’s AUC and
Tmax, but decreased the Cmax by 34% to 46%. Therefore, CYP3A inhibitors such as azol antifungals,
HIV protease inhibitors, clarithromycin, telithromycin, verapamil, diltiazem, indinavir, ciprofloxacin,
and grapefruit juice are not anticipated to have a significant effect on the pharmacokinetics of the
active metabolite.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) diltiazem (HOS-086288) protease (HOS-085623) ciprofloxacin (HOS-085177) ketoconazole (HOS-084513) grapefruit juice (HOS-088787) telithromycin (HOS-084523) clarithromycin (HOS-084517) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-22T14:15:00Z · SHA-256 bf0eaa99dea4480cd15ea241fb41ce985dc8e97851472df117f97dc0c795a95e · Passage c575bf610302710cfcda171888cb81be40ebe235dc41e06b6aeed5676196eca7 · Zeichen 2949–3489 im Abschnitt
Wechselwirkungen · Afinitor
Afinitor 2.5 mg tablets Afinitor 5 mg tablets Afinitor 10 mg tablets · Abschnitt 4.5 · PDF-Seite 9
HOS-210305 · Präparat HOS-154501
Active substance by Interaction – Change in Recommendations concerning
interaction Everolimus AUC/Cmax co-administration
Geometric mean ratio
(observed range)
Potent CYP3A4/PgP inhibitors
Ketoconazole AUC ↑15.3-fold Concomitant treatment of Afinitor
(range 11.2-22.5) and potent inhibitors is not
Cmax ↑4.1-fold recommended.
(range 2.6-7.0)
Itraconazole, posaconazole, Not studied. Large increase in
voriconazole everolimus concentration is
Telithromycin, expected.
clarithromycin
Nefazodone
Ritonavir, atazanavir,
saquinavir, darunavir,
indinavir, nelfinavir
Moderate CYP3A4/PgP inhibitors
Erythromycin AUC ↑4.4-fold Use caution when
(range 2.0-12.6) co-administration of moderate
Cmax ↑2.0-fold CYP3A4 inhibitors or PgP
(range 0.9-3.5) inhibitors cannot be avoided. If
Imatinib AUC ↑ 3.7-fold patients require co-administration
Cmax ↑ 2.2-fold of a moderate CYP3A4 or PgP
Verapamil AUC ↑3.5-fold inhibitor, dose reduction to 5 mg
(range 2.2-6.3) daily or 2.5 mg daily may be
Cmax ↑2.3-fold considered. However, there are no
(range1.3-3.8) clinical data with this dose
Ciclosporin oral AUC ↑2.7-fold adjustment. Due to between
(range 1.5-4.7) subject variability the
Cmax ↑1.8-fold recommended dose adjustments
(range 1.3-2.6) may not be optimal in all
Cannabidiol (PgP inhibitor) AUC ↑2.5-fold individuals, therefore close
Cmax ↑2.5-fold monitoring of side effects is
Fluconazole Not studied. Increased exposure recommended (see sections 4.2 and
Diltiazem expected. 4.4). If the moderate inhibitor is
Dronedarone Not studied. Increased exposure discontinued, consider a washout
expected. period of at least 2 to 3 days
Amprenavir, fosamprenavir Not studied. Increased exposure (average elimination time for most
expected. commonly used moderate
inhibitors) before the Afinitor dose
is returned to the dose used prior to
initiation of the co-administration.
Grapefruit juice or other Not studied. Increased exposure Combination should be avoided.
food affecting CYP3A4/PgP expected (the effect varies
widely).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) diltiazem (HOS-086288) nefazodone (HOS-084519) atazanavir (HOS-086180) nelfinavir (HOS-084520) dronedarone (HOS-086144) ketoconazole (HOS-084513) grapefruit juice (HOS-088787) cannabidiol (HOS-090609) imatinib (HOS-110212) voriconazole (HOS-084524) telithromycin (HOS-084523) itraconazole (HOS-084516) saquinavir (HOS-084522) fluconazole (HOS-087945) clarithromycin (HOS-084517) erythromycin (HOS-084514) amprenavir (HOS-086183) darunavir (HOS-086181) fosamprenavir (HOS-086182) ritonavir (HOS-084521) posaconazole (HOS-085622) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-20T11:21:00Z · SHA-256 678fc33837cd44d2e9320c5c80ffc02496b10803d7810e1b4f6e2d8e517263a0 · Passage 98d9f664e41c1a110308717f9cdec97f696053564a7a56a6d0f4d257ec0e0700 · Zeichen 1007–4534 im Abschnitt
Wechselwirkungen · Votrient
Votrient 200 mg film-coated tablets Votrient 400 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9
HOS-122558 · Präparat HOS-095539
Co-administration of pazopanib with other strong inhibitors of the CYP3A4 family (e.g. itraconazole,
clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin,
voriconazole) may increase pazopanib concentrations. Grapefruit juice contains an inhibitor of
CYP3A4 and may also increase plasma concentrations of pazopanib.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) nefazodone (HOS-084519) atazanavir (HOS-086180) nelfinavir (HOS-084520) grapefruit juice (HOS-088787) voriconazole (HOS-084524) telithromycin (HOS-084523) itraconazole (HOS-084516) saquinavir (HOS-084522) clarithromycin (HOS-084517) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-28T11:24:00Z · SHA-256 38e00132fe316301c56a9c9a4f9247483c54b55dd743bedaab120a272380aaff · Passage b42c756e6e6a2fa13f5954df2519e90091d64aef8b3e00883e77607a019cd19b · Zeichen 1494–1855 im Abschnitt
Wechselwirkungen · Eurartesim
Eurartesim 160 mg/20 mg film-coated tablets. · Abschnitt 4.5 · PDF-Seite 7
HOS-123027 · Präparat HOS-095623
Effect of co-administered medicinal products on Eurartesim
Piperaquine is metabolised by CYP3A4 in vitro. The concurrent administration of a single dose of oral
clarithromycin, (a strong CYP3A4 inhibitor probe) with a single dose of oral Eurartesim led to a
modest increase (≤2-fold) in piperaquine exposure in healthy adult subjects. This increase in exposure
to the antimalarial combination may result in an exacerbation of the effect on QTc (see section 4.4).
Therefore, particular caution is required if Eurartesim is administered to patients taking potent
CYP3A4 inhibitors (e.g. some HIV-protease inhibitors [atazanavir, darunavir, indinavir, lopinavir,
ritonavir], or verapamil and ECG monitoring should be considered due to the risk of higher plasma
concentrations of piperaquine (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) lopinavir (HOS-086269) atazanavir (HOS-086180) protease (HOS-085623) clarithromycin (HOS-084517) darunavir (HOS-086181) ritonavir (HOS-084521) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-04T13:58:00Z · SHA-256 dabfe6fde6102b83217e8e60df06f7976dca1a5f1a6c99e5db65545ad780075f · Passage c46259be380b997fd099f64ec164d5b20e6741c80a9f29bd8fd71a891e7b39f6 · Zeichen 2245–3051 im Abschnitt
Wechselwirkungen · Eurartesim
Eurartesim 320 mg/40 mg film-coated tablets. · Abschnitt 4.5 · PDF-Seite 22
HOS-123070 · Präparat HOS-095623
Effect of co-administered medicinal products on Eurartesim
Piperaquine is metabolised by CYP3A4 in vitro. The concurrent administration of a single dose of oral
clarithromycin, (a strong CYP3A4 inhibitor probe) with a single dose of oral Eurartesim led to a
modest increase (≤2-fold) in piperaquine exposure in healthy adult subjects. This increase in exposure
to the antimalarial combination may result in an exacerbation of the effect on QTc (see section 4.4).
Therefore, particular caution is required if Eurartesim is administered to patients taking potent
CYP3A4 inhibitors (e.g. some HIV-protease inhibitors [atazanavir, darunavir, indinavir, lopinavir,
ritonavir], or verapamil and ECG monitoring should be considered due to the risk of higher plasma
concentrations of piperaquine (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) lopinavir (HOS-086269) atazanavir (HOS-086180) protease (HOS-085623) clarithromycin (HOS-084517) darunavir (HOS-086181) ritonavir (HOS-084521) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-04T13:58:00Z · SHA-256 dabfe6fde6102b83217e8e60df06f7976dca1a5f1a6c99e5db65545ad780075f · Passage c46259be380b997fd099f64ec164d5b20e6741c80a9f29bd8fd71a891e7b39f6 · Zeichen 2242–3048 im Abschnitt
Wechselwirkungen · Jevtana
JEVTANA 60 mg concentrate and solvent for solution for infusion. · Abschnitt 4.5 · PDF-Seite 6–7
HOS-124033 · Präparat HOS-095771
6
Repeated administration of ketoconazole (400 mg once daily), a strong CYP3A inhibitor, resulted in a
20% decrease in cabazitaxel clearance corresponding to a 25% increase in AUC. Therefore
concomitant administration of strong CYP3A inhibitors (e.g., ketoconazole, itraconazole,
clarithromycin, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole)
should be avoided as an increase of plasma concentrations of cabazitaxel may occur (see sections 4.2
and 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) nefazodone (HOS-084519) nelfinavir (HOS-084520) ketoconazole (HOS-084513) voriconazole (HOS-084524) telithromycin (HOS-084523) itraconazole (HOS-084516) saquinavir (HOS-084522) clarithromycin (HOS-084517) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-30T13:04:00Z · SHA-256 4c1eff0507207d5beb179217fec464186ac3bc1330fa052cff48922b617d3c37 · Passage 6ce0e854043e4c44191bafd62a79322441f6096508dea8df3222ab048975ffeb · Zeichen 184–678 im Abschnitt
Wechselwirkungen · Edurant
EDURANT 25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-213939 · Präparat HOS-155234
(inhibition of CYP3A enzymes)
Other boosted PIs Not studied.
(atazanavir/ritonavir,
fosamprenavir/ritonavir,
saquinavir/ritonavir,
tipranavir/ritonavir)
HIV PIs – without co-administration of low dose ritonavir
Unboosted PIs Not studied. Increased exposure of No dose adjustment is required.
(atazanavir, rilpivirine is expected.
fosamprenavir, indinavir,
nelfinavir) (inhibition of CYP3A enzymes)
CCR5 Antagonists
Maraviroc Not studied. No clinically relevant No dose adjustment is required.
drug-drug interaction is expected.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) atazanavir (HOS-086180) nelfinavir (HOS-084520) saquinavir (HOS-084522) maraviroc (HOS-086186) fosamprenavir (HOS-086182) ritonavir (HOS-084521) tipranavir (HOS-086184)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-04-11T14:54:00Z · SHA-256 c02ae8018d7111133de16dc7b25339ee095e696ed781b3973764a15d8d998fed · Passage 60aea94064604081115f530963044425f19ad3a86812d0b4368b91a3d88618ef · Zeichen 4775–5443 im Abschnitt
Wechselwirkungen · Edurant
EDURANT 2.5 mg dispersible tablets · Abschnitt 4.5 · PDF-Seite 29
HOS-214000 · Präparat HOS-155234
(inhibition of CYP3A enzymes)
Other boosted PIs Not studied.
(atazanavir/ritonavir,
fosamprenavir/ritonavir,
saquinavir/ritonavir,
tipranavir/ritonavir)
HIV PIs – without co-administration of low dose ritonavir
Unboosted PIs Not studied. Increased exposure of No dose adjustment is required.
(atazanavir, rilpivirine is expected.
fosamprenavir, indinavir,
nelfinavir) (inhibition of CYP3A enzymes)
CCR5 Antagonists
Maraviroc Not studied. No clinically relevant No dose adjustment is required.
drug-drug interaction is expected.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) atazanavir (HOS-086180) nelfinavir (HOS-084520) saquinavir (HOS-084522) maraviroc (HOS-086186) fosamprenavir (HOS-086182) ritonavir (HOS-084521) tipranavir (HOS-086184)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-04-11T14:54:00Z · SHA-256 c02ae8018d7111133de16dc7b25339ee095e696ed781b3973764a15d8d998fed · Passage 7726ec9608e06b54ce400e3e41c65829af6dc2521312be062c35bd0ce99800e2 · Zeichen 4814–5495 im Abschnitt
Wechselwirkungen · Votubia
Votubia 2.5 mg tablets Votubia 5 mg tablets Votubia 10 mg tablets · Abschnitt 4.5 · PDF-Seite 11
HOS-214256 · Präparat HOS-155312
Active substance by Interaction – Change in Recommendations concerning
interaction Everolimus AUC/Cmax co-administration
Geometric mean ratio
(observed range)
Potent CYP3A4/PgP inhibitors
Ketoconazole AUC ↑15.3-fold Concomitant treatment of Votubia
(range 11.2-22.5) and potent inhibitors is not
Cmax ↑4.1-fold recommended.
(range 2.6-7.0)
Itraconazole, posaconazole, Not studied. Large increase in
voriconazole everolimus concentration is
Telithromycin, expected.
clarithromycin
Nefazodone
Ritonavir, atazanavir,
saquinavir, darunavir,
indinavir, nelfinavir
Moderate CYP3A4/PgP inhibitors
Erythromycin AUC ↑4.4-fold Use caution when co-administration
(range 2.0-12.6) of moderate CYP3A4 inhibitors or
Cmax ↑2.0-fold PgP inhibitors cannot be avoided.
(range 0.9-3.5)
Imatinib AUC ↑ 3.7-fold For patients with renal
Cmax ↑ 2.2-fold angiomyolipoma associated with
Verapamil AUC ↑3.5-fold TSC:
(range 2.2-6.3) If patients require co-administration
Cmax ↑2.3-fold of a moderate CYP3A4 or PgP
(range1.3-3.8) inhibitor, dose reduction to 5 mg or
Ciclosporin oral AUC ↑2.7-fold 2.5 mg daily may be considered.
(range 1.5-4.7) However, there are no clinical data
Cmax ↑1.8-fold with this dose adjustment. Due to
(range 1.3-2.6) between subject variability the
Cannabidiol (PgP inhibitor) AUC ↑2.5-fold recommended dose adjustments may
Cmax ↑2.5-fold not be optimal in all individuals,
Fluconazole Not studied. Increased exposure therefore close monitoring of side
Diltiazem expected. effects is recommended. If the
Dronedarone Not studied. Increased exposure moderate inhibitor is discontinued,
expected. consider a washout period of at least
Amprenavir, fosamprenavir Not studied. Increased exposure 2 to 3 days (average elimination time
expected. for most commonly used moderate
inhibitors) before the Votubia dose is
returned to the dose used prior to
initiation of the co-administration
(see also Therapeutic drug
monitoring in section 4.2).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) diltiazem (HOS-086288) nefazodone (HOS-084519) atazanavir (HOS-086180) nelfinavir (HOS-084520) dronedarone (HOS-086144) ketoconazole (HOS-084513) cannabidiol (HOS-090609) imatinib (HOS-110212) voriconazole (HOS-084524) telithromycin (HOS-084523) itraconazole (HOS-084516) saquinavir (HOS-084522) fluconazole (HOS-087945) clarithromycin (HOS-084517) erythromycin (HOS-084514) amprenavir (HOS-086183) darunavir (HOS-086181) fosamprenavir (HOS-086182) ritonavir (HOS-084521) posaconazole (HOS-085622) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-20T17:40:00Z · SHA-256 252b066ec590fdab1f3eb7eccacdb5c7e91ec79421c970096d1b5261820faba4 · Passage 874bc02290752e0fb541064d49638c0e5fad0c860b7d55032749ccc1bff1dcda · Zeichen 1008–4464 im Abschnitt
Wechselwirkungen · Votubia
Votubia 1 mg dispersible tablets Votubia 2 mg dispersible tablets Votubia 3 mg dispersible tablets Votubia 5 mg dispersible tablets · Abschnitt 4.5 · PDF-Seite 38
HOS-214306 · Präparat HOS-155312
Active substance by Interaction – Change in Recommendations concerning
interaction Everolimus AUC/Cmax co-administration
Geometric mean ratio
(observed range)
Potent CYP3A4/PgP inhibitors
Ketoconazole AUC ↑15.3-fold Concomitant treatment of Votubia
(range 11.2-22.5) and potent inhibitors is not
Cmax ↑4.1-fold recommended.
(range 2.6-7.0)
Itraconazole, posaconazole, Not studied. Large increase in
voriconazole everolimus concentration is
Telithromycin, expected.
clarithromycin
Nefazodone
Ritonavir, atazanavir,
saquinavir, darunavir,
indinavir, nelfinavir
Moderate CYP3A4/PgP inhibitors
Erythromycin AUC ↑4.4-fold Use caution when co-administration
(range 2.0-12.6) of moderate CYP3A4 inhibitors or
Cmax ↑2.0-fold PgP inhibitors cannot be avoided.
(range 0.9-3.5)
Imatinib AUC ↑ 3.7-fold If patients require co-administration
Cmax ↑ 2.2-fold of a moderate CYP3A4 or PgP
Verapamil AUC ↑3.5-fold inhibitor, reduce the daily dose by
(range 2.2-6.3) approximately 50%. Further dose
Cmax ↑2.3-fold reduction may be required to manage
(range1.3-3.8) adverse reactions (see sections 4.2
Ciclosporin oral AUC ↑2.7-fold and 4.4). Everolimus trough
(range 1.5-4.7) concentrations should be assessed at
Cmax ↑1.8-fold least 1 week after the addition of a
(range 1.3-2.6) moderate CYP3A4 or PgP inhibitor.
Cannabidiol (PgP inhibitor) AUC ↑2.5-fold If the moderate inhibitor is
Cmax ↑2.5-fold discontinued, consider a washout
Fluconazole Not studied. Increased exposure period of at least 2 to 3 days
Diltiazem expected. (average elimination time for most
Dronedarone Not studied. Increased exposure commonly used moderate inhibitors)
expected. before the Votubia dose is returned
Amprenavir, fosamprenavir Not studied. Increased exposure to the dose used prior to initiation of
expected. the co-administration. The
everolimus trough concentration
should be assessed at least 1 week
later (see sections 4.2 and 4.4).
Grapefruit juice or other Not studied. Increased exposure Combination should be avoided.
food affecting CYP3A4/PgP expected (the effect varies
widely).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) diltiazem (HOS-086288) nefazodone (HOS-084519) atazanavir (HOS-086180) nelfinavir (HOS-084520) dronedarone (HOS-086144) ketoconazole (HOS-084513) grapefruit juice (HOS-088787) cannabidiol (HOS-090609) imatinib (HOS-110212) voriconazole (HOS-084524) telithromycin (HOS-084523) itraconazole (HOS-084516) saquinavir (HOS-084522) fluconazole (HOS-087945) clarithromycin (HOS-084517) erythromycin (HOS-084514) amprenavir (HOS-086183) darunavir (HOS-086181) fosamprenavir (HOS-086182) ritonavir (HOS-084521) posaconazole (HOS-085622) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-20T17:40:00Z · SHA-256 252b066ec590fdab1f3eb7eccacdb5c7e91ec79421c970096d1b5261820faba4 · Passage ddc95e209a3f4d8e5376fa36e344d27d483981c2f805f567ef2fb4a51b8f3e0c · Zeichen 1012–4524 im Abschnitt
Wechselwirkungen · Docetaxel Kabi
DOCETAXEL KABI 20 mg/1 ml concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 11
HOS-214505 · Präparat HOS-155350
In case of combination with CYP3A4 inhibitors, the occurrence of docetaxel adverse reactions may
increase, as a result of reduced metabolism. If the concomitant use of a strong CYP3A4 inhibitor (e.g.,
ketoconazole, itraconazole, clarithromycin, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir,
telithromycin and voriconazole) cannot be avoided, a close clinical surveillance is warranted and a
dose-adjustment of docetaxel may be suitable during the treatment with the strong CYP3A4 inhibitor
(see section 4.4). In a pharmacokinetic study with 7 patients, the co-administration of docetaxel with
the strong CYP3A4 inhibitor ketoconazole leads to a significant decrease in docetaxel clearance by
49%.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) nefazodone (HOS-084519) nelfinavir (HOS-084520) ketoconazole (HOS-084513) voriconazole (HOS-084524) telithromycin (HOS-084523) itraconazole (HOS-084516) saquinavir (HOS-084522) clarithromycin (HOS-084517) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-08-04T15:44:00Z · SHA-256 4ec115d98d201d84de2340a9fdabdd8a6db17b0a20954d72cafab8a7e3eaf6e6 · Passage f640897b581648a671549528599a0e77c0e915b1bc7804c45ad024fcf812c54f · Zeichen 778–1486 im Abschnitt
Wechselwirkungen · Docetaxel Kabi
DOCETAXEL KABI 80 mg/4 ml concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 57
HOS-214631 · Präparat HOS-155350
In case of combination with CYP3A4 inhibitors, the occurrence of docetaxel adverse reactions may
increase, as a result of reduced metabolism. If the concomitant use of a strong CYP3A4 inhibitor (e.g.,
ketoconazole, itraconazole, clarithromycin, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir,
telithromycin and voriconazole) cannot be avoided, a close clinical surveillance is warranted and a
dose-adjustment of docetaxel may be suitable during the treatment with the strong CYP3A4 inhibitor
(see section 4.4). In a pharmacokinetic study with 7 patients, the co-administration of docetaxel with
the strong CYP3A4 inhibitor ketoconazole leads to a significant decrease in docetaxel clearance by
49%.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) nefazodone (HOS-084519) nelfinavir (HOS-084520) ketoconazole (HOS-084513) voriconazole (HOS-084524) telithromycin (HOS-084523) itraconazole (HOS-084516) saquinavir (HOS-084522) clarithromycin (HOS-084517) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-08-04T15:44:00Z · SHA-256 4ec115d98d201d84de2340a9fdabdd8a6db17b0a20954d72cafab8a7e3eaf6e6 · Passage f640897b581648a671549528599a0e77c0e915b1bc7804c45ad024fcf812c54f · Zeichen 778–1486 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.